Bioxyne Limited · ASX:BXN
Bioxyne — BLS Pharmaceuticals — Shareholder Meeting (July 2012)
11 slides from Bioxyne's shareholder meeting presentation, Jul 17, 2012
Slide 1: Chairman's Address Shareholder Briefing
For personal use only Chairman’s Address Shareholder Briefing July 2012 1
Slide 2: Disclaimer
Disclaimer For personal use only From me for what I am about to discuss, there is none I am going to discuss: • The decision to conduct HI – H005 • HI – H005; its results and what the data may be signaling • Our Messages to the Market • The Future • Board Composition • Our Cash Position Our Managing
Slide 3: Basis for HI-H005
Basis for HI – H005 For personal use only HI - H 002 & 4 multi centre Phase 2 safety and efficacy studies HI - H003 Phase 1 safety and mechanism study HI - H002 • 90% reduction in hospital admissions • 56% reduction in antibiotic use • 56% reduction in corticosteroid therapy 3
Slide 4: Preparation for HI-H005
Preparation for HI - H005 For personal use only Team for the Trial • Professor Clancy • Dr Doug Wilson • Dr John Bienenstock – Mc Masters University • Professor Peter Calverley – Liverpool University • Professor Christine Jenkins - University of Sydney • Dr Dennis Niewoehner – University of Minnesot
Slide 5: Misses End Points
HI – H005 Misses End Points For personal use only Trial • Dosing – March to June 2011 • Data Lock – End May 2012 • Board Advised –14 June 2012 • Market advised – the trial did not deliver on the defined end points. June 28th Continuous Disclosure • Missed the end points • Burden to establish value C
Slide 6: Signals from Data
Signals from Data For personal use only Continuous Enquiry - Why the difference and what does the data tell us? .. there is something of a disconnect between the scientific approach to the data obtained on the one hand and the “rules of the game” about assessing clinical trial results on the other.
Slide 7: Experts Will Weigh Significance of Signals
Experts Will Weigh Significance of Signals For personal use only HI - H002 (Chest) v HI - H005 - The HI-002: Sputum .. samples were collected to monitor bacteria colonization HI - H005 protocol provided: A sputum sample will be collected .. if the patient is able to provide one. This sample will be
Slide 8: Ways Forward
Ways Forward For personal use only The ways forward: • abandonment • valuation • board composition • new ventures • trade sale or licence • partnering Trade sale or licence – possibly morphing in to partnering • Torreya Partners – timetable • package to market –today (~50) • NDA–end August • Non-bin
Slide 9: Board
Board For personal use only Board composition: • internal must deliver the skill set needed to supervise the business • driven by shareholders Redefinition is part of the continuum • present board skill set focused on sale or licecing • change in business will drive change in board composition (i.e.
Slide 10: Cash
Cash For personal use only Burn Rate is Being Reduced in line with business: • Board • Managing Director • Consultants • Newcastle Research Centre • Administration 10
Slide 11: For personal use only
For personal use only 11
BLS Pharmaceuticals — Shareholder Meeting (July 2012) on 6ix